News

€10m for crop research
Enlarge image

FundingFranceGermanyPortugalSpain

€10m for crop research

31.07.2012 - The transnational plant genome research funding initiative PLANT-KBBE has published its 6th call: €10m will be provided for crop breeding projects.

The acronym PLANT-KBBE stands for: 'Transnational PLant Alliance for Novel Technologies – towards implementing the Knowledge-Based Bio-Economy in Europe' (PLANT-KBBE) and represents an international funding initiative between France, Spain, Germany and Portugal. National funding partners are the Ministry of Research and Innovation (DGRI) in France, represented by the national funding agency ANR (Agence Nationale de la Recherche), the Ministry of Economy and Competitiveness (MINECO) in Spain, the Federal Ministry of Education and Research (BMBF) in Germany and the Portuguese national funding agency FCT (Fundação para a Ciênca e a Tecnologia). 

Purpose of the call, which is the 6th transnational ‘Call for Proposals’ (‘Food & Feed: crop yields and nutrition security in the context of climate change‘) is the accelerated implementation of practical applications based on achieved scientific findings, accompanied with an immediate transfer of research results in new processes, products and services. The programme targets projects  that are based on the following general research themes: Yield stability, plant health, adaptation to pressures from the environment and phenotypic plasticity. 

The higher purpose of the PLANT-KBBE funding initiative is the implementation, as well as continuation, of transnational research projects between research groups and enterprises of the partner countries mentioned above, with the objective of further deepening the already existing cooperation between economy and science in and between these countries. In the framework of PLANT-KBBE, SMEs are  particularly addressed. The funding partners also intend to support such multi-disciplinary R&D-activities in the context of public-private-partnerships, integrating other research fields apart from plant biotechnology. Full proposals are to be submitted by October 15.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-26.8%
  • PROSENSA (NL)9.48 USD-25.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • PROSENSA (NL)9.48 USD-68.0%

No liability assumed, Date: 25.07.2014